The UK's first weight loss pill has arrived: what it means for patients

Quick answer: The Wegovy tablet, a once-daily oral version of the weight loss injection, launched with private providers this week after MHRA approval on 11 June 2026. It is private-only for now, needs a prescription, and as of 9 July 2026 there is no confirmed timeline for NHS access.

This week, UK pharmacies started dispensing the first oral version of Wegovy, a tablet form of the injectable weight loss drug that has dominated headlines for the past two years. Some of the coverage has called it a turning point for obesity treatment. That's broadly fair, but a few details are getting lost in the noise. Here's what's actually changed, why the format matters, and where it leaves patients weighing up their options.

What's changed, and what hasn't

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy tablet, oral semaglutide, on 11 June 2026. It's the first GLP-1 medicine in tablet form to be licensed in the UK specifically for weight management, and from Monday 6 July 2026 it started going on sale through private pharmacies and online providers, initially in the lower 1.5mg and 4mg strengths.

A couple of things this isn't. It isn't an NHS approval. NHS funding decisions are made separately, through NICE, and haven't happened for this medicine yet. If you want the fuller picture of how NHS eligibility for GLP-1 medicines currently works, that's covered in our dedicated guide. And it isn't a new drug. The active ingredient, semaglutide, is the same one already used in the Wegovy injection and in Ozempic. What's changed is how it's delivered, not what it is.

It's also a different product to Rybelsus, an oral semaglutide tablet that's already been on the market for a while. Rybelsus is licensed for type 2 diabetes, at lower doses, up to 14mg. The new Wegovy tablet is licensed for weight management and goes up to 25mg. The two aren't interchangeable, and a prescription for one doesn't cover the other.

Why the format matters

For patients, the obvious change is no more injections, and unlike the pre-filled Wegovy pen, no need to keep it in the fridge. That could make treatment more manageable for people who are needle-averse, or whose routine doesn't suit a weekly injection day.

It comes with its own discipline, though. The tablet has to be taken on an empty stomach after fasting for at least eight hours, with a specific and limited amount of water (up to half a glass), and swallowed whole rather than crushed or split, followed by a further 30-minute wait before eating, drinking, or taking other oral medicines. Miss that routine, and the amount of drug actually absorbed is materially reduced. One kind of hassle gets swapped for another. Our full guide to the Wegovy oral tablet goes through the dosing routine, eligibility, and side effects in more detail.

There's also a manufacturing angle. Tablets are generally cheaper to produce at scale than pre-filled injector pens, and some in the industry have pointed to that as a reason the pill could eventually widen supply. For a fuller breakdown of what these medicines cost across providers, see our GLP-1 costs guide.

The bigger picture on obesity

Much of the coverage has set this launch against the scale of obesity in England. Around two in three adults here are currently overweight or living with obesity, 64.5% as of 2023/24 on official government figures, rising to 66% in the most recent measured Health Survey for England. The Department of Health and Social Care puts the direct NHS cost of obesity-related care at around £6.5 billion a year; a newer independent analysis commissioned by Nesta puts UK-wide NHS spending on treating obesity-related ill health specifically at £9.3 billion annually, within a wider estimated £126 billion total economic cost of obesity and excess weight. Against that, NHS-funded access to GLP-1 medicines is still narrow: for example, NHS plans for tirzepatide (Mounjaro) in primary care aim to reach around 220,000 people over three years, against an estimated 3.4 million adults who'd meet the clinical criteria, with full rollout not expected for up to 12 years. On most estimates, the large majority of people currently taking these medicines in the UK are paying for them privately.

That gap is the backdrop this launch is being reported against. A pill that's easier to take doesn't, on its own, close it. If you're trying to weigh up the NHS and private routes for weight loss medication more broadly, our NHS versus private comparison guide sets out the trade-offs in more detail.

A pill is easier to fake

Pharmacy bodies have raised a specific worry about the tablet format: that it may be easier for criminal operations to counterfeit than an injectable pen, which is harder to fake convincingly. In a snap survey of 310 pharmacies carried out by the National Pharmacy Association in the first days of July 2026, 97% of respondents said they were concerned the tablet would fuel a rise in fake or unlicensed weight-loss medicines on the black market. The advice from pharmacy leaders is consistent: only get this medicine through a registered pharmacy or a provider that carries out a proper clinical consultation, and be wary of prices or offers that look too good to be true.

Does this bring NHS access any closer?

For anyone hoping this launch brings NHS access closer, the honest answer is not yet. New medicines typically go through a NICE technology appraisal before any NHS funding decision, and for comparable obesity drugs that process has taken well over a year in practice. The injectable Wegovy pen, for instance, was approved by the MHRA in September 2021 but didn't get its NICE recommendation until March 2023, roughly 18 months later. As of 9 July 2026, NICE has not published or announced a technology appraisal specifically for the oral Wegovy tablet, so there's no timeline to point to yet, and NHS access within 2026 looks unlikely.

The pattern is a familiar one. The NHS rollout of Mounjaro for obesity, which began in primary care in June 2025 following its own NICE appraisal, has been phased and slow relative to demand: initial funding was set up to cover only a fraction of the estimated 3.4 million adults who could qualify, with full rollout planned to take up to 12 years. There's no reason to expect the oral Wegovy tablet to move any faster.

Where that leaves you

If you're considering this medicine, it's currently a private-only option. It requires a prescription following a clinical assessment, the same as the injectable versions, and there's no safe or legal way to get it without one. If you're weighing up NHS versus private routes for weight management more broadly, nothing about the calculation has changed with this launch: NHS options exist but come with longer waits and stricter eligibility criteria, while private options are faster to access but carry an ongoing cost.